Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to compare the pharmacokinetics (PK) of a single oral 75
mg dose of cabozantinib in hepatic impaired adult subjects to healthy adult subjects. Another
objective is to assess the safety and tolerability of cabozantinib in these adult subjects.